Menu Search
Equities

Affluent Medical SAS

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0JZ:FRA

Affluent Medical SAS

Actions
  • Price (EUR)3.37
  • Today's Change0.04 / 1.20%
  • Shares traded3.36k
  • 1 Year change+153.38%
  • Beta0.4739
Data delayed at least 15 minutes, as of Feb 12 2026 07:55 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Affluent Medical SAS is a France-based company that manufactures surgical implants. It designs minimally invasive prostheses at mimicking human anatomy and restoring native physiology for critical functions in cardiovascular and urological therapies. It provides several products such as Kalios, Epygon, Artus. It helps in treating heart disease and urinary incontinence. The Company provides transcatheter and flow control technologies, such as mimicry of anatomy and restoration of physiology minimally invasive implant procedures, optimized and biocompatible components.

  • Revenue in EUR (TTM)4.12m
  • Net income in EUR-14.74m
  • Incorporated2018
  • Employees76.00
  • Location
    Affluent Medical SAS320 avenue ArchimedeLes pleiades III Batiment BAIX-EN-PROVENCE 13100FranceFRA
  • Phone+33 442951220
  • Websitehttps://www.affluentmedical.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		CVX:PAR since
announced		Transaction
value
Caranx Medical SASDeal completed19 Dec 202519 Dec 2025Deal completed132.84%--
Artedrone SASDeal completed19 Dec 202519 Dec 2025Deal completed132.84%--
Data delayed at least 15 minutes, as of Feb 12 2026 12:07 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.